Background {#Sec1}
==========

ID (intellectual disability) and ASD (autism spectrum disorder) are life-long conditions with deficits in cognitive functioning (IQ\<70) and adaptive skills that affects 1--3 % of children worldwide \[[@CR1]\]. Array-CGH (aCGH) offers a high diagnostic yield, ranging from 14--20 %, for individuals with unexplained ID, ASD or multiple congenital anomalies (MCA) \[[@CR2]--[@CR5]\]. Available evidence suggests a change in the diagnostic approach for children with neuropsychiatric disorders and/or congenital anomalies, indicating the aCGH as the first-tier cytogenetic diagnostic test \[[@CR5]\]. In 2014 the SIGU (Italian Society of Human Genetics) suggested that ID, of all severity, and/or ASD and/or epilepsy, hypotonia, dysmorphisms, growth alteration, congenital malformations might be associated with pathogenic aCGH results.

The chromosomal imbalances detected by aCGH are defined copy number variations (CNVs) that are referred as: microdeletions and microduplications of clear clinical relevance or pathogenic, variants of uncertain significance (VOUS) and benign polymorphisms \[[@CR6]--[@CR8]\]. The advances in molecular methodology of aCGH technology, *along with its* broader application, facilitated the detection of novel pathogenic CNVs. The significance of many VOUS still remains uncertain causing serious problems in defining their contribution in patients affected by ID, MCA and ASD \[[@CR9]--[@CR13]\].

The aim of this study was twofold:To determine phenotypic clues associated to pathogenic CNVs, outlining criteria for selecting patients to be studied with aCGH as first-line test.To identify cytogenetic criteria of VOUS to be taken into account for their potentially pathogenicity.

These aims allow us to depict an integrative flow-chart applying for children with ID.

Study design {#Sec2}
============

We present a retrospective-prospective study including 214 patients. In order to establish which patients could mostly benefit of aCGH as first molecular test, we tried to individuate clinical and anamnestic clues that significantly correlate with pathologic aCGH data. For this purpose, all the subjects received a complete history recall and an accurate clinical and instrumental evaluation. All the anamnestic-clinical-investigation data, either as a single feature or in combination, were correlated to pathologic or negative aCGH results.

Our second aim was to identify cytogenetic elements that could predict the pathological role of VOUS. We characterized meticulously all the VOUS detected, recording: the size of the rearrangements, the presence of deletions, duplications or multiple rearrangements and the genic density. We correlated the cytogenetic data with the severity of the phenotype. A severe phenotype was defined on the presence of severe ID, ASD and multiple malformations.

On the basis of inferred results, we define a flow-chart applying for children with ID.

Patients and methods {#Sec3}
====================

Patients {#Sec4}
--------

We enrolled 214 patients (114 males and 100 females with an average age of 5.63 years, range 1.3--19 years), with or without variable degree of ID, and/or ASD and/or MCA. They had been referred and evaluated at the Clinical Genetic Unit of the Translational Medical Science Department, section of Pediatrics, of the University of Naples "Federico II" in a 10-year period (2002--2012): 91 patients were recruited (47 male and 44 female, age range 1.7--19 years, mean 5.1 years) from 2002--2006, and followed up, so belonged to a retrospective part of the study; 123 patients (69 male and 54 female, age range 8 month-11years, mean 6.16 years) were enrolled in the prospective part of the study from 2006--2012.

Methods {#Sec5}
=======

Clinical-anamnestic data {#Sec6}
------------------------

The diagnostic workup started with a meticulous family history recall, physical examination focused on the presence of minor (dysmorphology evaluation) and major anomalies, neurological exam and assessment of the behavioral phenotype as detailed in the Additional file [1](#MOESM1){ref-type="media"}*.*

Instrumental evaluation {#Sec7}
-----------------------

The diagnostic instrumental evaluation included: brain MRI, abdominal ultrasound, echocardiography, EEG and ABR. Not all the investigations were performed due to the lack of patient cooperation or parental consent. For patients who underwent brain MRI the association between brain structural anomalies and the presence of ID (moderate/severe), microcephaly, macrocephaly, hearing loss, EEG abnormalities was evaluated.

Metabolic screening tests {#Sec8}
-------------------------

A metabolic screening panel (plasma amino acids, acylcarnitine profile, urine organic acids, ammonia and lactic acid) was performed. Targeted metabolic tests (lysosomal enzymes, urine oligosaccharides, transferrin isoform profile, plasma sterol concentrations, congenital glycosylation defects) were carried out when clinical suspect arose.

Cytogenetic analysis {#Sec9}
--------------------

For patients included in the retrospective part, initial tests to exclude genetic syndromes suspected based on the facial and gestalt phenotypes or due to initial unavailability of aCGH were performed, including: karyotype (standard and high resolution type), specific loci (22q11.2, 7q11.23, 16p13.3) and/or subtelomeric FISH, DNA methylation analysis for Prader-Willi and Angelmann syndrome and FRAX-A/E test. Since a diagnosis was not achieved through these procedures, aCGH with an average resolution of 500 Kb was performed. In patients enrolled in the prospective part of the study, aCGH with a resolution of 50--75 Kb was used as first tier test. Different platforms have been used along with progressive improvement of aCGH technology. Despite this could represent a bias we could not analyze again all the patients previously studied in the retrospective part with a lower resolution power. We re-analyzed only few patients with clinical features strongly suggestive for chromosomal disorder and showing normal results. These results have been considered in the prospective part of the study.

Cytogenetic techniques applied and CNVs interpretative processes are included in Additional file [1](#MOESM1){ref-type="media"}*.*

The CNVs size, the presence of multiple rearrangements and the number of genes located in were assessed. Patients with overlapping chromosomal rearrangements have been compared and studied.

Statistical analysis {#Sec10}
--------------------

Clinical data were assessed using a standardized protocol (excel sheet) for collection of data in all children. SPSS software (version 20.0; SPSS Inc., Chicago, IL, USA) and R (version 2.5.0; The R Foundation for Statistical Computing) were used for the statistical analysis. Analyses included only available data and missing values were not imputed. Data were summarized as means ± standard deviation (median \[25^th^--75^th^ percentile\]) for continuous variables and as frequencies (%) for categorical variables. The association between the presence of a pathogenic CNV (as opposed to a normal array CGH results) with clinical characteristics (including ID, ASD, and familiarity with ID and with several anomalies/malformations) was based on a standard two-step approach. In particular, univariate association between each predictor and the aCGH results were first established using chi-square test (or the fisher exact test when appropriate); afterward, those factors showing a bivariate association with the dependent variable at a *p*\<0.2 were entered in a multivariate logistic regression model using a backward stepwise method for the selection of variables. The discriminatory ability of the final model was assessed using ROC curve analysis. In order to correct the area under the ROC curve (AUC) for over-optimism, which occurs when the fit of a model is evaluated using the same data in which the model was built, a bootstrap procedure as described in \[[@CR14]\] was used. The exact Mann--Whitney U test was used for comparing children with and without ID in case of VOUS with respect to the following variables: presence of deletions/duplications, number of multiple rearrangements, average size of rearrangements and genetic density.

Results {#Sec11}
=======

Clinical data {#Sec12}
-------------

In our cohort 168/214 patients showed ID: mild, moderate and severe ID was identified in 129, 25 and 14 patients respectively. All the clinical findings recorded along with their frequency are shown in Table [1](#Tab1){ref-type="table"}.Table 1Clinical features recorded in each patient expressed as percentage in are providedSigns/symptomsPercentage of patientsIntellectual disabilitySevere6.5 %Moderate12 %Mild60 %Absent21.5 %Autism spectrum disorder17.2 %Familiarity for ID and/or MCA8 %Prenatal perinatal problems14 %Short stature19.15 %Tall stature2.8 %Macrocephaly7 %Microcephaly (Craniosynostosis included)31 %Forehead and eyebrows phenotypic abnormalities38 %Eyes, palpebral fissures and eyelashes phenotypic abnormalities54 %Nose and phyltrum phenotypic abnormalities37 %Oral region, teeth and tongue phenotypic abnormalities49 %Ears phenotypic abnormalities37 %Neck and thorax phenotypic abnormalities18 %Upper limbs, lower limbs, hands and feet phenotypic abnormalies26 %Gastrointestinal malformations (megacolon, Duodenal/Esophageal stenosis)16 %Neurology (Epilepsy, hypertonia, hypotonia, paresis, extrapyramidal signs)14 %Cardiac malformations33 %Pulmonary malformations1 %Kidney and urinary tract anomalies8 %Abnormal external genitalia12 %Ocular malformation16 %Vertebral anomalies22 %Skeletal dysplasia5 %Haematological abnormalities3 %Nails and hair anomalies13 %Alterated skin pigmentation or skin hemangioma13.3 %Endocrinological abnormalities10 %

Instrumental evaluation {#Sec13}
-----------------------

All the results from instrumental evaluation are presented in Table [2](#Tab2){ref-type="table"}. Currently, a consensus on the role of neuroimages in patients with ID has not been achieved. Brain MRI findings have to be considered of contributory value but not essential in defining a genetic diagnosis or in the assessment of children with ID. Brain MRI was performed in 122 out 214 patients (57 %) and 57 of 122 (47 %) showed structural malformations in line with previous report \[[@CR3]\]. To date consensus to perform brain MRI include macrocephaly, microcephaly, asymmetric neurologic signs, intractable epilepsy or focal seizures, abnormal movements, hypotonia or progressive neurological disorder \[[@CR2], [@CR15]\]. In our cohort we did not find any correlation between brain MRI pathological findings and microcephaly (*p*= 0.652) or macrocephaly (*p*=0.473). Conversely pathologic MRI findings were correlated with both moderate/severe ID (*p*=0.046) and neurosensitive hearing loss (*p*=0.01).Table 2Genetic and Instrumental tests performed in the cohort are indicatedDiagnostic testsPercentage of patients testing pathologicPercentage of patients performing the testABR39 %41 %EEG37 %29 %Brain MRI47 %57 %Karyotype0 %71 %FRAX-A0 %26 %Prader-Willi/Angelman0 %6 %FISH 22q11.20 %6 %FISH 7q110 %2 %Rubinstein-Taybi0 %6 %Subtelomeric rearrangements analysis0 %6 %Other molecular analyses0 %21 %Plasma amino acids and acylcarnitines0 %59 %Urine organic acids0 %46 %Plasmatic ammonia and lactic acid0 %40 %Oligosaccharides (urine)0 %13 %Glycosaminoglycans (urine)0 %11 %Serum transferrin isoform profiling0 %9 %Sterols (plasma)0 %6 %Percentages of positive and negative results are pointed out

Metabolic profile {#Sec14}
-----------------

The metabolic screening panel consisting in: plasma amino acids, acylcarnitine profile, urine organic acids, ammonia and lactic acid were applied in around 50 % of patients. In specific cases lysosomal storage disease were partially ruled out performing lysosomal enzymes assay, urine oligosaccharides and glycosaminoglycans. Transferrin isoform profiling and sterols were performed only in 9 and 6 % of patients (Table [2](#Tab2){ref-type="table"}).

Cytogenetic analysis results {#Sec15}
----------------------------

### Detection rate {#Sec16}

Pathological aCGH results was obtained in 65 patients (30 males and 35 females) (30 %), 124 patients (58 %) showed negative results or benign CNVs, while in 25 cases (12 %) VOUS were detected (Fig. [1](#Fig1){ref-type="fig"}). Figure [2](#Fig2){ref-type="fig"} summarizes genetic loci of all detected pathogenic CNVs and VOUS. Pathological CNVs showed the highest average size of chromosomal rearrangement and gene content, a higher prevalence of deletions and of multiple rearrangements than those detected in VOUS and benign CNVs (Table [3](#Tab3){ref-type="table"}).Fig. 1ACGH results are depictedFig. 2Overview of 90 chromosomal imbalances by aCGH (VOUS and pathogenic results included). See Legend for interpretation of markersTable 3Cytogenetic features of detected CNVsAverage size of chromosomal rearrangement (kb)DeletionsDuplicationsGene ContentMultiple chromosomal rearrangements (number of patients)VOUS (25)523.3013132.739Pathological CNV (65)7018.2654234.6729Benign (26)364.7219252.5211It should be noticed that pathogenic CNVs shared larger rearrangements, high number of deletions and multiple rearrangements

### Specific syndromes {#Sec17}

The diagnosis of already known genetic syndromes was achieved in 47 patients (data not shown). For Cri-du-chat syndrome, DiGeorge syndrome, 1q21.1 deletion syndrome, 1q21.2 deletion syndrome, 3q29 deletion syndrome, 6p25 deletion syndrome, 6q duplication syndrome, 13q12.3 deletion syndrome and 16p11.2 deletion syndrome, more than one case was recorded. The comparison of these cases might widen the phenotype associated to microdeletion syndromes and might contribute to a more careful study of critical regions containing haplosensitive genes. Furthermore, 18 pathogenic novel chromosomal rearrangements have been discovered as well.

### Correlation study results {#Sec18}

Table [4](#Tab4){ref-type="table"} shows the distribution of the clinical features and anomalies/malformations in children with pathogenic and negative aCGH results. In a univariate analysis, the only predictive factors of pathologic array results were: ASD and positive family history for ID/MCA/ASD. No significant differences in the frequencies of facial and non-facial dysmorphic features, congenital anomalies were recorded. ID, dysmorphic eyes anomalies, conductive and neurosensorial hearing loss, neurological signs (epilepsy, hypertonia, hypotonia, and paresis), cutaneous dyschromia and endocrinological problems were considered as potential predictors due to an association with the outcome at a liberal p value of 0.2. A multivariable logistic regression model with backward selection, showed that ID (OR 2.57; 95 % CI \[1.07--6.2\]; *p*=0.035), familiarity with ID/MCA/ASD (OR 11.4; 95 % CI \[3.21--40.49\]; *p*=\<0.001), and cutaneous dyschromia (OR 2.75; 95 % CI \[1.19--6.34\]; *p*=0.018) were all independent predictors of a pathogenic CNV and yielded an optimism-corrected estimate of the overall accuracy, in terms of AUC, of 0.69 (the bootstrap estimate of the optimism in AUC was very small and equal to 0.01). The Chi-square Hosmer and Lemeshow were equal to 4.78 with a p value of 0.44. We enrolled 37 patients with ASD, in presence or absence of ID, 23 males and 14 females. Seventeen showed pathological CNVs and 4 VOUS. 12 patients carried out one or more microduplications, 9 microdeletions and 2 both microdeletion and microduplication.Table 4Correlations between single and combined clinical features and pathogenic and negative aCGH results are shownClinical signs, dysmorphic featuresaCGH results (number)Negative (115)Pathological (60)Overall (175)*p*Intellectual Disability83 (72.2)49 (81.7)132 (75.4)0.166Autism Spectrum Disorders13 (11.3)14 (23.3)27 (15.4)0.037Familiarity for ID/MCA/ASD3 (2.6)9 (15)12 (6.9)0.002Prenatal perinatal problems17 (14.8)9 (15)26 (14.9)0.934Short stature21 (18.3)12 (20)33 (18.9)0.781Tall stature3 (2.6)1 (1.7)4 (2.3)1.000Macrocephaly8 (7)4 (6.7)12 (6.9)1.000Microcephaly (or craniosynostosis)30 (26.1)16 (26.7)46 (26.3)0.934Forehead and Eyebrows dysmorphisms41 (35.7)21 (35)62 (35.4)0.932Eyes, palpebral fissures and eyelashes dysmorphisms53 (46.1)36 (60)89 (50.9)0.081Nose and philtrum dysmorphisms40 (34.8)23 (38.3)63 (36)0.642Oral region, teeth and tongue dysmorphisms45 (39.1)28 (46.7)73 (41.7)0.337Ears dysmorphisms43 (37.4)24 (40)67 (38.3)0.736Neck and thorax anomalies21 (18.26)14 (23.73)35 (20.11)0.394Upper and lower limbs, hands, feet dysmorphisms24 (20.9)12 (20)36 (20.6)0.893Hearing Loss15 (13)13 (21.7)28 (16)0.140Gastrointestinal malformations15 (13)5 (8.3)20 (11.4)0.353Brain Malformations13 (11.3)8 (13.3)21 (12)0.695Neurologic signs (Epilepsy, hypertonia, hypotonia, paresis)15 (13)4 (6.7)19 (10.9)0.198Cardiac malformations36 (31.3)23 (38.3)59 (33.7)0.350Pulmonary malformations2 (1.7)1 (1.7)3 (1.7)1.000Kidney and urinary tract anomalies3 (2.6)1 (1.7)4 (2.3)1.000Abnormal external genitalia15 (13)7 (11.7)22 (12.6)0.794Eye malformations12 (10.4)7 (11.7)19 (10.9)0.804Vertebral anomalies29 (25.8)14 (23)43 (24.57)0.718Skeletal dysplasia7 (6.1)3 (5)10 (5.7)1.000Haematological abnormalities2 (1.7)3 (5)5 (2.9)0.219Nails and hair anomalies16 (13.9)6 (10.2)22 (12.6)0.482Alterated skin pigmentation8 (7)9 (15)17 (9.7)0.088Skin hemangioma3 (2.6)1 (1.7)4 (2.3)1.000Endocrinological anomalies9 (7.8)9 (15)18 (10.3)0.138Statistical significant correlations exist between pathologic CNVs and ASD and familiarity for ID/ASD/MCA. Other clinical features: ID (independent from severity), dysmorphisms of eyes, palpebral fissures and eyelashes, Hearing Loss, neurologic signs, abnormal skin pigmentation and endocrinological anomalies) appear to be potential predictors of pathological aCGH results

### Characterization of uncertain CNV (VOUS) {#Sec19}

Different clinical features (as single data or in combination) were correlated to cytogenetic features of *de novo* VOUS (CNVs dimension, presence of deletion vs duplication, genic density, presence of multiple different CNVs) (Table [5](#Tab5){ref-type="table"}). We found that in children with ID, VOUS had a significantly higher gene density than in patients without ID (*p*=0.019). No associations were found between VOUS cytogenetic data and other analyzed clinical features (ASD, short stature, tall stature, macrocephaly, microcephaly, craniosynostosis, hearing loss, hepatic and gut malformation, brain malformation, epilepsy, heart malformation, genitourinary malformation, eye malformations, skeletal dysplasias, immunological anomalies, skin hyper/depigmentation, endocrinological problems). Moreover the severity of clinical phenotype did not correlate with any cytogenetic characteristics shared by VOUS.Table 5Evaluation of cytogenetic indicator in VOUS suggests that gene density is the only parameter associated to IDIntellectual disabilityAbsent (*n*=4)Mild/Moderate (*n*=21)Total (*n*=25)*p*Deletion; *n* (%)3 (75 %)10 (47.6 %)13 (52 %)0.593CNV dimension; Median \[25^th^ 75^th^ percentile\]367.5 \[145.75;801.5\]258 \[160.5;791\]258 \[160.5;791\]0.902Genic densitiy; Median \[25^th^ 75^th^ percentile\]0.5 \[0;1\]2 \[1;4.25\]2 \[1;3.25\]0.019Multiple CNVs; Median \[25^th^ 75^th^ percentile\]1 \[1;2.5\]1 \[1;2\]1 \[1;2\]0.858

### Suggested diagnostic flow-chart {#Sec20}

Since ID/ASD/MCA are conditions of great concern and deserve special care, a flow-chart regarding the most appropriate care for patients with ID (including metabolic screening test, neuroimaging evaluation, diagnostic molecular investigations) has been depicted on the basis of the data inferred from this study (Fig. [3](#Fig3){ref-type="fig"}). We matched the data we obtained with the large-scale studies sharing a similar aim \[[@CR16]--[@CR19]\]. In the present work we could not use the combined technology "aCGH and single-nucleotide polymorphism (SNP) array". We suggest to use this combination, when available, to detect CNVs plus a limited amount of SNP data to screen for absence of heterozygosity \[[@CR19]\].Fig. 3Algorithm in patients with unexplained ID and/or and/or ASD. After the collection of appropriate clinical and family history, you need to take a detailed physical and dysmorphology examination. If patient has a recognizable pattern of signs and symptoms you have to confirm diagnosis by cytogenetic or molecular targeted test. Nonetheless the infrequent detection rate Fragile X A/E syndrome should be excluded in all patients with ID. If the patient does not present with features of recognizable syndrome or metabolic disorder or the latter resulted negative for a suspected syndromes aCGH is the first-tier test especially in case of ASD diagnosis or family history positive for ID/MCA/ASD. Other potential predictors of pathogical results are: ocular anomalies, hearing loss, neurological signs, cutaneous dyscromia and endocrinological problems. If aCGH comes back negative further clinical investigations are warranted. If the detected CNV includes relevant region/genes or the gene content and its size meet guidelines criteria the result has to be considered pathogenic. In such cases parental studies and evaluation of cytogenetic feature as gene density could aid in ascertain their likely pathogenicity

Discussion {#Sec21}
==========

ID is a developmental disability, which presents in infancy or early childhood characterized by impaired intellectual functioning and adaptive behavior. The prevalence is estimated between 1 and 3 % of children \[[@CR5], [@CR20]--[@CR22]\]. ASDs are clinically heterogeneous disorders that include: autism, Asperger syndrome, pervasive developmental disorders not otherwise specified, and childhood disintegrative disorder. ASD ha*s* been estimated to affect 1/100 to 1/150 children \[[@CR3]\]. Many children with ASD also have ID representing together the most frequent referral to geneticists for a diagnostic workup. American Academy of Pediatrics Committee has discussed the importance of early identification of the cause of neurocognitive phenotype identifying several benefits \[[@CR3]\]. Since even small chromosomal anomalies have been established as a major cause of ID and ASD, aCGH test has become an important diagnostic tool for patients at least sharing neuro-phenotypes \[[@CR2]--[@CR5]\].

Despite a very high number of studies describing genetic findings of CNVs, we identifed a high rate of pathologic CNVs, more frequently deletions, in a cohort of patients with ID and/or ASD. High gene content is also found in patients with VOUS and ID.

We also demonstrated that a positive family history for ID/ASD/MCA (cardiologic, renal, intestinal anomalies) and ASD were two good independent indicator of pathologic CNVs.

On the basis of our data we suggest that aCGH should be used as first tier diagnostic test in the presence of ID/ASD/MCA. We also underline the importance of family historical recall and of parents' clinical observation in order to evaluate the presence of ID/ASD in the parents.

Among VOUS, higher gene density was found in patients affected by ID.

A diagnosis of metabolic disorders has been reported in 1--5 % of patients with ID \[[@CR3], [@CR19], [@CR23], [@CR24]\]. Diagnostic evaluation for inborn errors of metabolism (IEMs) was performed in 126 patients giving normal data. Notwithstanding, metabolic studies should be thoroughly considered in patients with ID due to the potential treatability of IEMs.

ACGH was performed in patients included in the retrospective part of this study because of negative results of other genetic studies, while it was applied as first tier test in the prospective part of the study because growing number of papers highlighted its diagnostic power \[[@CR25]--[@CR27]\]. We identified 65 (30 %) and 25 (12 %) patients with pathogenic CNVs and VOUS respectively. The detection rate of clinically significant CNVs is about 30 % therefore higher than the yields (from 14.2--21.1 %) obtained from studies that used similar platforms \[[@CR2], [@CR3], [@CR5], [@CR10], [@CR28]--[@CR30]\]. We speculate that the higher prevalence of pathological CNVs in our study is potentially ascribed to the careful selection of patients. Among patients with pathological CNVs, the deletions were more frequent than duplications (65 vs 42) being the former more commonly interpreted as pathogenic \[[@CR10]\]. The pathogenic CNVs have a higher size (7 Mb) and gene density (35 genes) than VOUS and benign ones in agreement with other reports \[[@CR29], [@CR31], [@CR32]\]. 29 patients with pathological CNVs have multiple rearrangements, which are known to exacerbate neuro-developmental phenotypes (Table [3](#Tab3){ref-type="table"}) \[[@CR5], [@CR32]\]. In these patients parental chromosomal study did not reveal balanced translocations.

We diagnosed 47 patients (22 %) with OMIM syndromes on the basis of either overlapping described well- microdeletion/microduplication syndromes or known causing-genes mapped within chromosomal rearrangements. ACGH detected CNVs scattered throughout the genome, but the chromosome 1, 8, 22, X resulted most frequently involved in line with other reports \[[@CR33]\]. The non-random involvement of specific chromosomal segments could be the results of non-allelic homologous recombinant mutational mechanism \[[@CR29]\]. Other recurrent pathogenic CNVs involved 1q21.1, 1q41q42, 2p15, 16p13.1, 16p11.2, 17q21.31 allowing us to characterize the phenotypes associated to chromosomal rearrangements in these specific regions \[[@CR30], [@CR34]--[@CR39]\]. A specific chromosomal abnormality does not always correspond to a specific or suggestive phenotype. In such cases, the detection of genomic aberration precedes the definition of specific phenotypes \[[@CR30]\]. In our dataset patients with 22q11.21 deletion and Cri-du-chat syndromes showed an atypical phenotype making the clinical diagnosis challenging \[[@CR40]\].

The potential limitations of aCGH application regard: delayed turnaround time, the impossibility of the detection of balanced translocations and low-level mosaicisms, the high costs, so that clinical criteria for selection of patients with higher probability of pathogenic CNV are desirable.

The selection of patients who are most likely to have a diagnosis by aCGH, minimizing the number of benign CNVs or negative results, remains an attractive goal \[[@CR41]\]. This study represents the largest collection of specific clinical and instrumental data for which an association with pathologic CNVs has been investigated. From previous studies, the same rate of pathologic chromosomal imbalances by aCGH was found in unselected and selected patients (\[[@CR18], [@CR41]\] respectively). Other studies found the higher frequency of pathogenic CNVs in patients with congenital anomalies, unspecified dysmorphisms, growth anomalies, heart defects, primary microcephaly and familial occurrence of ID \[[@CR22], [@CR42]--[@CR44]\]. The diagnostic yield among patients with more severe ID would be expected to be higher than in patients with milder ID \[[@CR45]--[@CR47]\]. In our cohort, 47 patients were enrolled because of MCA and they did not show ID. Indeed pooling data from patients with different ID degree and without ID, we conclude that more severe ID is not statistically related to pathogenic CNVs \[[@CR4], [@CR5], [@CR29]\]. Among the consistent number of clinical and history data analyzed, positive family history for ID/MCA/ASD and isolated ASD were found to be associated to pathological aCGH results. We would underline that other congenital anomalies as ocular dysmorphisms (*p*=0.062), hearing loss (*p*=0.127), neurological signs (*p*=0.103), cutaneous dyscromia (*p*=0.08) and endocrinological system involvement (*p*=0.128) are potentially predictors of pathological CNVs.

In this cohort, 37 patients were affected by ASD. The overall diagnostic yield of aCGH for patients with ASD ranges from 18.2--22 % \[[@CR45], [@CR48]--[@CR50]\]. In our cohort the diagnostic yield is consistently greater (around 44 %, 16 patients out 37). Among ASD patients of this case-study, pathogenic CNVs are mostly located at chromosome 1, 4, 6, 8, 21 and 22, that partially confirm the previous results from the literature \[[@CR45], [@CR51]\]. In the present study we found a low frequency of abnormal FRAX-A test results as previously described \[[@CR19]\].

Some hesitations in using aCGH in clinical setting diagnostic test derive from the difficulties in the efficient discrimination between benign, VOUS and pathogenic CNVs \[[@CR2], [@CR11], [@CR52]\]. CNVs can be interpreted as abnormal (pathological CNVs), VOUS and benign. We interpreted CNVs as pathogenic when contained: critical regions of microdeletion/microduplication known syndromes, genes associated with autosomal dominant inherited diseases and when cases with similar phenotypes and overlapping CNVs have already reported. CNVs are likely to be benign if they are reported in controls databases (similar CNVs in at least three healthy individuals in the same "sense", with an overlap of more than the 50 % and the not-overlapped part less than 100 Kb), if they do not contain genes and/or known regulatory elements. Comparative analysis, with data listed in available large datasets, guide toward the clarification of CNVs clinical impact and interpretation. Multiple sources were considered as level of documentation. All the identified CNVs have been compared to those listed in: the Database of Genomic Variants (DGV, <http://projects.tcag.ca/variation>) that includes healthy individuals, the pathogenic CNVs databases for patients with ID, ASD and MCA: as the International Standard Cytogenomic Array Consortium Databases (ISCA, <https://www.clinicalgenome.or>), as well as the Database of Chromosomal Imbalance and Phenotype in Humans using Ensemble Resources (DECIPHER, https://decipher.sanger.ac.uk/). The Database of Genomic Structural Variation (dbVar, <http://www.ncbi.nlm.nih.gov/dbvar>) including structural variation from both normal control population and disease population has been consulted as well. The genes, involved in the chromosomal region of interest, and their functions have been checked by UCSC Genome Browser (http:// <http://genome-euro.ucsc.edu/cgi-bin/hgGateway>) and Ensamble Genome Browser (<http://www.ensembl.org/index.html>). In the interpretative process, each gene, within the CNV as well as neighboring genes, was studied for its potential role in neurological development, by all the available evidence along sources as OMIM, Genereviews, PubMed. The CNVs not associated with previously reported pathogenicity or benignity criteria were estimated as VOUS. The potential pathogenicity of VOUS is reported to be determined by many factors: the "sense" of the rearrangement (deletion or duplication, as the penetrance of duplications is considered lower than of deletions), the size (pathogenic imbalances tend to be larger than benign) and the gene content \[[@CR7]\]. We detected and analyzed 25 de novo VOUS and evaluated some cytogenetic indicators: overall size, gain vs loss, presence of multiple rearrangements (complex rearrangements involving several CNVs) and gene content. Only gene content had a significant correlation with ID. The gene content should be evaluated in order to speculate the pathogenicity of VOUS \[[@CR7], [@CR10], [@CR53]\].

Due to presence of VOUS, incomplete penetrance, and variable expressivity of CNVs the role of genetic counseling in aCGH testing and CNVs interpretation complements the diagnostic testing. Moreover pre-test counseling cannot be underestimated and should review potential benefits and limitations of the test.

Conclusion {#Sec22}
==========

The achievement of a specific genetic diagnosis improves medical care and allows an accurate recurrent risk counselling for the family. ACGH enables: discovering emerging new syndromes and variable presentations of already characterized ones, deciphering the genetic bases of many syndromes by discovering candidate genes. The current study highlights that a checklist of clinical features for preselecting cases for aCGH analysis with high sensitivity and specificity is difficult to attain. The positive family history for ID/MCA/ASD and the presence of ASD seem to be independent additional clues positively associated to causative CNVs. Among other criteria, ID (with no correlation with the level), eyes anomalies, hearing loss and other neurological signs, cutaneous dyscromia, endocrinological system involvement were also deemed as potentially predictive factor of pathogenic CNVs. VOUS involving gene-rich regions are more frequently associated to ID and pathological phenotypes.

What's Known on This Subject {#Sec23}
============================

Array-CGH has been defined the first line diagnostic tool in patients sharing intellectual disability and multiple congenital abnormalities. The diagnostic yield is still low and interpretative issues of the results remain elusive.

What This Study Adds {#Sec24}
====================

Phenotypic clues predictive of pathological results have been defined to help in patients' selection to be studied with array-CGH. Cytogenetic features of rearrangements to be taken into account are provided; variant of uncertain significance showed higher density in patients sharing intellectula disability. A revised flow-chart for patients with intellectual disability is depicted.

Ethics {#Sec25}
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:   array-CGH

ABR

:   brainstem auditory evoked potentials

ASD

:   autism spectrum disorder

CNVs

:   copy number variation

EEG

:   electroencephalogram
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:   inborn errors of metabolism
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:   multiple congenital anomalies
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